← Back to Search


Glutamate Imaging and Cognitive Testing for Depression

Led By Irina Esterlis, PhD
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Medication-free for at least 2 weeks or medicated with a permissible medication for acute depressed subjects
Clinical diagnosis of a current depressive episode for acute depressed subjects
Must not have
Have history of a bleeding disorder or are currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto)
Have active, significant suicidal ideation
Screening 3 weeks
Treatment Varies
Follow Up through study completion date, an average of 4 years.
Awards & highlights


This trialstudies how glutamate affects depression and requires MRI/PET scans, cognitive testing, and 1-2 months of participation.

Who is the study for?
This trial is for adults aged 18-65 with certain psychiatric conditions like depression, bipolar disorder, or PTSD. It's also open to healthy individuals without any DSM-5 diagnosis. Participants must be English-speaking and medication-free or on approved meds for at least two weeks.Check my eligibility
What is being tested?
The study examines the glutamate system in mental health by using PET scans, MRI imaging, and cognitive tests over 1-2 months. The goal is to understand how this system differs among those with psychiatric disorders compared to healthy controls.See study design
What are the potential side effects?
While not a treatment trial, procedures may include discomfort from lying still during scans, potential anxiety from enclosed spaces in MRI machines, and exposure to radiation within FDA limits.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I haven't taken any medication for the last 2 weeks or only allowed medications for depression.
I am currently experiencing a depressive episode.
I have been diagnosed with PTSD according to DSM-5 criteria.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
I have a bleeding disorder or am on blood thinners like Coumadin.
I am currently experiencing strong thoughts of harming myself.
I am currently pregnant or breastfeeding.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion date, an average of 4 years.
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion date, an average of 4 years. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Evidence of glutamate availability (mGluR5) in psychiatric disorders confirmed by MRI and PET data.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Cognitive TestingExperimental Treatment1 Intervention
Cognitive assessments
Group II: Magnetic Resonance ImagingActive Control1 Intervention
All subjects will have one MRI with a possibility of one functional MRI (fmri).
Group III: Positron Emission TomographyActive Control1 Intervention
All subjects will have PET scan using FPEB or ABP688.

Find a Location

Who is running the clinical trial?

Yale UniversityLead Sponsor
1,874 Previous Clinical Trials
2,953,376 Total Patients Enrolled
VA Office of Research and DevelopmentFED
1,628 Previous Clinical Trials
3,325,799 Total Patients Enrolled
Irina Esterlis, PhDPrincipal InvestigatorYale School of Medicine
3 Previous Clinical Trials
299 Total Patients Enrolled

Media Library

MRI (Other) Clinical Trial Eligibility Overview. Trial Name: NCT02727972 — N/A
MRI (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02727972 — N/A
Post-Traumatic Stress Disorder Research Study Groups: Cognitive Testing, Magnetic Resonance Imaging, Positron Emission Tomography
Post-Traumatic Stress Disorder Clinical Trial 2023: MRI Highlights & Side Effects. Trial Name: NCT02727972 — N/A
Post-Traumatic Stress Disorder Patient Testimony for trial: Trial Name: NCT02727972 — N/A
~13 spots leftby Aug 2025